max_frisch
The biggest risk is not taking any risk
- Joined
- Oct 26, 2022
- Posts
- 1,629
- Reputation
- 1,995
first of all, i condem all antisemitc stuff that is posted here (even though majority might be trolling). i sympathize with israel and the struggle of the many jewish posters here such as @David Rothschild face (antisemitism)
it came recently to my acknowledge however, that some people here claim that finasteride is a "jewish invention". i want to make perfectly clear that i dont have a problem with jewish inventions, jewish inventors whatsoever.
however im always for the truth and the truth alone. hence i cannot let this false statement stand.
FINASTERIDE IS NOT A JEWISH INVETION
Noone in the process was jewish.
as you can see the two main protagonist in the invention, developing and marketing of finasteride are
1. Dr. Imperato-McGinley
2. P. Roy Vagelos
it came recently to my acknowledge however, that some people here claim that finasteride is a "jewish invention". i want to make perfectly clear that i dont have a problem with jewish inventions, jewish inventors whatsoever.
however im always for the truth and the truth alone. hence i cannot let this false statement stand.
FINASTERIDE IS NOT A JEWISH INVETION
Noone in the process was jewish.
How was finasteride invented?
Although finasteride came on the market in the 1990s, the underlying research began two decades earlier. The rationale for the drug emerged from a study of a unique group of people in a remote village in the Dominican Republic called Las Salinas. Locals there have long known about children who follow an unusual developmental path: they are initially raised as girls, but around age 12 they develop male characteristics. They are known locally as guabidós or guevedoces.1
The village of Las Salinas, where researchers investigated individuals with an intersex condition in the early 1970s, is in the southwestern part of Dominican Republic near the border with Haiti.
In 1972, endocrinologist Julianne Imperato-McGinley, colleagues at Cornell, and a Dominican doctor traveled to Las Salinas to study people with this condition. They identified 24 people in 13 families who had been born with female or ambiguous genitalia, but developed male traits at puberty, a process they called virilization. The researchers observed a few traits which were different from typical males: when mature, they had no enlargement of their prostate, no acne and no recession of their hairline.
Dr. Imperato-McGinley and colleagues reported their findings in a series of papers, the first of which appeared in Science in 1974. The studied individuals were found to have a deficiency of the enzyme 5-alpha reductase (5-AR) which is needed for the conversion of testosterone into another androgen called dihydrotestosterone (DHT). Today, the condition is called 5-alpha reductase deficiency.
The enzyme 5-alpha reductase (5-AR) enables the conversion of testosterone to dihydrotestosterone (DHT). Individuals studied in Las Salinas had a congenital deficiency of 5-AR, and therefore low levels of DHT. In the 1980s, pharmaceutical companies developed compounds to recreate this deficiency in adults by inhibiting 5-AR, thereby lowering DHT levels. One of these was finasteride which would be approved by FDA in 1992 for the treatment of an enlarged prostate.
Because of the 5-AR deficiency, these individuals had low levels of DHT throughout their lives. Since DHT is required for male genitals to develop early in gestation, babies lacked male genitals at birth even though they had a male (XY) genotype. As mentioned earlier, around age 12 they developed male traits and tended to acquire a male psychosexual orientation. As they matured into adulthood, there were a few differences with typical male traits: people with 5-AR deficiency did not have enlarged prostates, acne or recession of their hairline. Researchers deduced that normal levels of 5-AR—and therefore DHT—are associated with prostate growth, acne and hair loss in men.
A drug development opportunity is identified
The President of Merck, Roy Vagelos, came across this research and identified a drug development opportunity: if 5-AR could be inhibited in adult males, it might emulate the traits associated with 5-AR deficiency, such as reduced growth of the prostate. Slowing prostate growth could treat a condition in aging men which causes urinary symptoms. Other possible applications were treatment of acne or slowing of hair loss. During the 1980s, Merck and other pharmaceutical companies undertook scientific work to develop a new class of drugs: 5-alpha reductase inhibitors.
as you can see the two main protagonist in the invention, developing and marketing of finasteride are
1. Dr. Imperato-McGinley
Mcginley Name Meaning
Irish (Donegal): Anglicized form of Gaelic Mag Fhionnghaile ‘son of Fionnghal’ a personal name composed of the elements fionn ‘fair’ + gal ‘valor’.
The surname Imperato was first found in Sardinia (Italian: Sardegna, Sardinian: Sardigna), the second largest island in the Mediterranean Sea.
2. P. Roy Vagelos
Vagelos grew up during the Depression as a son of Greek immigrants.
How was finasteride invented?
Although finasteride came on the market in the 1990s, the underlying research began two decades earlier. The rationale for the drug emerged from a study of a unique group of people in a remote village in the Dominican Republic called Las Salinas. Locals there have long known about children who follo
finasterideinfo.org
Last edited: